Literature DB >> 11967475

A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder.

Timothy E Wilens1, Thomas J Spencer, Joseph Biederman.   

Abstract

OBJECTIVE: Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, the use of pharmacotherapeutics remains less established.
METHODS: A systematic review of the literature identified 15 studies (N = 435 subjects) of stimulants, and 22 studies of non-stimulant medications (N = 421 subjects) including antidepressants, antihypertensives, amino acids, and wake-promoting agents for the treatment of ADHD in adults.
RESULTS: Studies with stimulants and antidepressants demonstrated significant short-term improvement in ADHD symptoms compared to placebo in adults. Methylphenidate (MPH) and amphetamine had an immediate onset of action whereas the ADHD response to pemoline and antidepressants appeared delayed. The response to amphetamine and MPH appears to be dose-dependent. Controlled data on nicotonic and noradrenergic compounds appear promising. There was considerable variability in diagnostic criteria, dosing parameters, and response rates between the various studies.
CONCLUSIONS: Under controlled conditions, the aggregate literature shows that the stimulants and noradrenergic antidepressants had a clinically and statistically significant beneficial effect on treating ADHD in adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967475     DOI: 10.1177/108705470100500401

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  49 in total

1.  Efficacy of meta-cognitive therapy for adult ADHD.

Authors:  Mary V Solanto; David J Marks; Jeanette Wasserstein; Katherine Mitchell; Howard Abikoff; Jose Ma J Alvir; Michele D Kofman
Journal:  Am J Psychiatry       Date:  2010-03-15       Impact factor: 18.112

2.  Adult ADHD: Diagnosis, Differential Diagnosis, and Medication Management.

Authors:  Julie P Gentile; Rafay Atiq; Paulette M Gillig
Journal:  Psychiatry (Edgmont)       Date:  2006-08

Review 3.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

4.  Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Current Empirical Support, Treatment Overview, and Future Directions.

Authors:  John T Mitchell; Lidia Zylowska; Scott H Kollins
Journal:  Cogn Behav Pract       Date:  2015-05

Review 5.  Developmental context and treatment principles for ADHD among college students.

Authors:  Andrew P Fleming; Robert J McMahon
Journal:  Clin Child Fam Psychol Rev       Date:  2012-12

Review 6.  Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.

Authors:  Alexandra S Potter; Geoffrey Schaubhut; Megan Shipman
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 7.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

8.  Differential Behavioral and Biochemical Responses to Caffeine in Male and Female Rats from a Validated Model of Attention Deficit and Hyperactivity Disorder.

Authors:  Fernanda Nunes; Daniela Pochmann; Amanda Staldoni Almeida; Daniela Melo Marques; Lisiane de Oliveira Porciúncula
Journal:  Mol Neurobiol       Date:  2018-03-20       Impact factor: 5.590

9.  Extended access to amphetamine self-administration increases impulsive choice in a delay discounting task in rats.

Authors:  Cassandra D Gipson; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2009-09-26       Impact factor: 4.530

10.  Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.

Authors:  Rajasree Nair; Shannon B Moss
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.